# Expanded Access for AG-221

> **NCT03723057** · — · NO_LONGER_AVAILABLE · sponsor: **Celgene**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** AG-221

## Key facts

- **NCT ID:** NCT03723057
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723057, "Expanded Access for AG-221". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03723057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*